IRVINE,
Calif., Feb. 27, 2025 /PRNewswire/ -- American
Healthcare REIT, Inc. (the "Company," "we," "our," "management," or
"us") (NYSE: AHR) announced today its fourth quarter and full year
2024 results and is issuing full year 2025 guidance.
Key Highlights:
- Reported GAAP net loss attributable to controlling interest of
$(31.8) million and GAAP net loss
attributable to common stockholders of $(0.21) per diluted share for the three months
ended December 31, 2024. Reported
GAAP net loss attributable to controlling interest of $(37.8) million and GAAP net loss attributable to
common stockholders of $(0.29) per
diluted share for the year ended December
31, 2024.
- Reported Normalized Funds from Operations attributable to
common stockholders ("NFFO") of $0.40
and $1.41 per diluted share for the
three months and year ended December 31,
2024, respectively.
- Achieved total portfolio Same-Store Net Operating Income
("NOI") growth of 21.6% and 17.7% for the three months and year
ended December 31, 2024,
respectively, compared to the same periods in 2023.
- Achieved 66.6% and 28.0% Same-Store NOI growth during the three
months ended December 31, 2024, from
its senior housing operating properties ("SHOP") and integrated
senior health campuses ("ISHC"), respectively, compared to the same
period in 2023. Achieved 52.8% and 23.8% Same-Store NOI growth
during the year ended December 31,
2024, from its SHOP and ISHC segments, respectively,
compared to the same period in 2023.
- During the year ended December 31,
2024, the Company purchased over $650
million of new investments. During the three months ended
December 31, 2024, the Company
acquired a SHOP asset in the Atlanta MSA for a total consideration
of approximately $7.5 million, before
closing and transaction costs.
- In November, the Company established an at-the-market equity
offering program ("ATM program") allowing the Company to sell
shares of common stock for aggregate gross proceeds of up to
$500 million. During the three months
ended December 31, 2024, the Company
issued 4,285,531 shares of common stock from its ATM program,
raising gross proceeds of approximately $120.2 million. During the year ended
December 31, 2024, the Company raised
total gross proceeds of approximately $1.36
billion through its equity offerings and ATM program.
- The Company is issuing total portfolio Same-Store NOI growth
guidance of 7.0% to 10.0% and NFFO per diluted share guidance of
$1.56 to $1.60 for the year ending December 31, 2025.
- Reported a 4.2x improvement in the Company's Net
Debt-to-Annualized Adjusted EBITDA from 8.5x as of December 31, 2023, to 4.3x as of December 31, 2024.
"We have much to be proud of in AHR's first year as a listed
Healthcare REIT," said Danny Prosky,
the Company's President and Chief Executive Officer. "We delivered
strong earnings and achieved attractive NOI growth across our
diversified healthcare portfolio. As we look ahead to 2025, the
supply and demand fundamentals within the healthcare real estate
industry remain robust. AHR is steadfast in its commitment to
delivering high-quality care and performance across our facilities.
This year, we expect to deliver both solid earnings per share and
Same-Store NOI growth, building on the successful year we had in
2024."
Fourth Quarter 2024 and Full-Year 2024 Results
The Company's Same-Store NOI growth results for the three months
and year ended December 31, 2024, are
detailed below. Same-Store NOI growth results from its managed
portfolio, comprised of ISHC and SHOP segments, led the Company's
growth in 2024, compared to 2023, supported by occupancy growth and
NOI margin expansion over the course of the year.
Three Months Ended
December 31, 2024 Relative to Three Months Ended
December 31, 2023
|
Segment
|
Same-Store NOI
Growth
|
ISHC
|
28.0 %
|
Outpatient
Medical
|
1.3 %
|
SHOP
|
66.6 %
|
Triple-Net Leased
Properties
|
1.7 %
|
Total
Portfolio
|
21.6 %
|
|
Year Ended
December 31, 2024 Relative to Year Ended December 31,
2023
|
Segment
|
Same-Store NOI
Growth
|
ISHC
|
23.8 %
|
Outpatient
Medical
|
0.5 %
|
SHOP
|
52.8 %
|
Triple-Net Leased
Properties
|
3.2 %
|
Total
Portfolio
|
17.7 %
|
"Our portfolio focus on senior housing investments proved to be
a winning strategy as senior housing fueled strong total portfolio
Same-Store NOI growth in 2024," said Gabe
Willhite, the Company's Chief Operating Officer. "Our
ISHC and SHOP segments once again produced exceptional results in
the fourth quarter with 28.0% and 66.6% year-over-year Same-Store
NOI growth, respectively. I believe deeply that partnering
with a highly-curated list of operating partners in combination
with our ability to provide more focused asset management support,
continue to be key differentiators driving our performance and
demonstrating the strength of our platform. In 2025, we
expect continued growth driven by strong senior housing
fundamentals, which we anticipate to produce outsized revenue
growth opportunities relative to expense growth and sustained
margin expansion."
Transactional Activity
As previously announced, on October 1,
2024, the Company acquired a SHOP asset located in the
Atlanta MSA consisting of 90 units for approximately $7.5 million, before closing and transaction
costs, reflecting a price per unit of approximately $83,750. Operations at the property were
transitioned to Senior Solutions Management Group, one of the
Company's existing regional operators, in a RIDEA structure.
Subsequent to quarter end, the Company is under contract to
acquire two SHOP assets for approximately $70.5 million. The transactions are expected to
close in the first half of 2025. Both SHOP properties are expected
to be operated by two of the Company's existing regional operators.
Additionally, the Company also completed a lease buyout within its
ISHC segment for approximately $15.9
million.
During the year ended December 31,
2024, the Company purchased over $650
million of new investments, including the minority
membership interest in Trilogy Holdings that had been held by a
joint venture partner. The Company has approved new ISHC
development projects, including new campuses, independent living
villas, and campus and wing expansions that will begin construction
in 2025, with total expected construction costs of approximately
$136.6 million.
As previously announced, on October 16,
2024, the Company sold one Outpatient Medical building for
approximately $19.4 million.
Additionally, during the three months ended December 31, 2024, the Company sold 10 properties
from its Outpatient Medical, Triple-Net Leased Properties and ISHC
segments for approximately $120.5
million. During the year ended December 31, 2024, the Company sold approximately
$155.5 million of properties from
various segments, further refining its portfolio and using proceeds
to pay down debt or allocate capital to better risk-adjusted return
opportunities, such as SHOP acquisitions and ISHC development.
Subsequent to quarter end, the Company sold one SHOP property
for approximately $3.3 million.
Capital Markets and Balance Sheet Activity
As of December 31, 2024, the Company's total consolidated
indebtedness was $1.69 billion, and
it had approximately $984.3 million of total liquidity, comprised
of cash, restricted cash and undrawn capacity on its lines of
credit. The Company's Net-Debt-to-Annualized Adjusted EBITDA as of
December 31, 2024, was 4.3x.
During the three months ended December
31, 2024, the Company established an ATM equity offering
program, pursuant to which it may, from time to time, offer and
sell shares of common stock for aggregate gross proceeds of up to
$500 million. During the three months
ended December 31, 2024, the Company
issued 4,285,531 shares of common stock through its ATM program for
gross proceeds of approximately $120.2
million, at an average price of $28.05 per share. As of December 31, 2024, the remaining amount available
under the ATM program for future sales of common stock was
approximately $379.8
million.
"Our guidance reflects our expectation that 2025 will be another
year of strong earnings growth, building on the excellent
double-digit Same-Store NOI growth delivered in 2024," said
Brian Peay, the Company's Chief
Financial Officer. "Additionally, we were able to strategically
raise additional equity at attractive pricing and utilize those
proceeds to buy out the remainder of Trilogy and also dramatically
improve our balance sheet. I am very proud of the team's efforts
this year, creating capacity to allow us to continue to execute on
our business plan while ending the year with Net Debt-to-
Annualized Adjusted EBITDA of 4.3x."
Full Year 2025 Guidance
The Company is issuing guidance for the year ending December 31, 2025. The Company's 2025 guidance
does not assume any additional transaction or capital markets
activity beyond the items disclosed in this earnings release.
Guidance ranges are detailed below:
|
Full Year 2025
Guidance
|
Full Year 2024
Results
|
Metric
|
Midpoint
|
FY 2025
Range
|
Net income (loss) per
diluted share
|
$0.28
|
$0.26 to
$0.30
|
$(0.29)
|
NAREIT FFO per diluted
share
|
$1.51
|
$1.49 to
$1.53
|
$1.26
|
NFFO per diluted
share
|
$1.58
|
$1.56 to
$1.60
|
$1.41
|
Total Portfolio SS NOI
Growth
|
8.5 %
|
7.0% to
10.0%
|
17.7 %
|
Segment-Level SS
NOI
|
|
|
|
Growth /
(Decline):
|
|
|
|
ISHC
|
11.0 %
|
10.0% to
12.0%
|
23.8 %
|
Outpatient
Medical
|
0.0 %
|
(1.0%) to
1.0%
|
0.5 %
|
SHOP
|
20.0 %
|
18.0% to
22.0%
|
52.8 %
|
Triple-Net Leased
Properties
|
(1.0 %)
|
(1.5%) to
(0.5%)
|
3.2 %
|
|
|
|
|
|
Certain of the
assumptions underlying the Company's 2025 guidance can be found
within the Non-GAAP reconciliations in this earnings release and in
the appendix of the Company's Fourth Quarter 2024 Supplemental
Financial Information ("Supplemental"). A reconciliation of net
income (loss) calculated in accordance with GAAP to NAREIT FFO and
NFFO can be found within the Non-GAAP reconciliations in this
earnings release. Non-GAAP financial measures and other terms, as
used in this earnings release, are also defined and further
explained in the Supplemental. The Company is unable to provide
without reasonable effort guidance for the most comparable GAAP
financial measures of total revenues and property operating and
maintenance expenses. Additionally, a reconciliation of the
forward-looking Non-GAAP financial measures of Same-Store NOI
growth to the comparable GAAP financial measures cannot be provided
without unreasonable effort because the Company is unable to
reasonably predict certain items contained in the GAAP measures,
including non-recurring and infrequent items that are not
indicative of the Company's ongoing operations. Such items include,
but are not limited to, impairment on depreciated real estate
assets, net gain or loss on sale of real estate assets, stock-based
compensation, casualty loss, non-Same-Store revenues and
non-Same-Store operating expenses. These items are uncertain,
depend on various factors and could have a material impact on the
Company's GAAP results for the guidance period.
|
Distributions
As previously announced, the Company's Board of Directors
declared a cash distribution for the quarter ended December 31, 2024 of $0.25 per share of its common stock. The fourth
quarter distribution was paid in cash on January 17, 2025, to stockholders of record as of
December 31, 2024.
Supplemental Information
The Company has disclosed supplemental information regarding its
portfolio, financial position and results of operations as of, and
for the three months ended, December 31,
2024, and certain other information, which is available on
the Investor Relations section of the Company's website at
https://ir.americanhealthcarereit.com.
Conference Call and Webcast Information
The Company will host a webcast and conference call at
1:00 p.m. Eastern Time on
February 28, 2025. During the
conference call, Company executives will review fourth quarter 2024
results, provide additional comments on its 2025 guidance, discuss
recent events and conduct a question-and-answer period.
To join via webcast, investors may use the following link:
https://events.q4inc.com/attendee/718447410.
To join the live telephone conference call, please dial one of
the following numbers at least five minutes prior to the start
time:
North America - Toll-Free:
(800) 715-9871
International Toll: +1 (646) 307-1963
Conference ID: 2930459
A digital replay of the call will be available on the Investor
Relations section of the Company's website at
https://ir.americanhealthcarereit.com shortly after the conclusion
of the call.
Forward-Looking Statements
Certain statements contained in this press release, including
statements relating to the Company's expectations regarding its
interest expense savings, balance sheet, net income or loss per
diluted share, FFO per diluted share, NFFO per diluted share, total
portfolio Same-Store NOI growth, segment-level Same-Store NOI
growth or decline, occupancy, NOI growth, revenue growth, margin
expansion, purchases and sales of assets, construction plans, and
plans for Trilogy may be considered forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The Company intends for all such forward-looking
statements to be covered by the applicable safe harbor provisions
for forward-looking statements contained in those acts. Such
forward-looking statements generally can be identified by the use
of forward-looking terminology, such as "may," "will," "can,"
"expect," "intend," "anticipate," "estimate," "believe,"
"continue," "possible," "initiatives," "focus," "seek,"
"objective," "goal," "strategy," "plan," "potential,"
"potentially," "preparing," "projected," "future," "long-term,"
"once," "should," "could," "would," "might," "uncertainty" or other
similar words. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. Any such forward-looking statements are
based on current expectations, estimates and projections about the
industry and markets in which the Company operates, and beliefs of,
and assumptions made by, the Company's management and involve known
and unknown risks and uncertainties that could cause actual results
to differ materially from those expressed or implied therein,
including, without limitation, risks disclosed in the Company's
Annual Report on Form 10-K for the year ended December 31, 2024, expected to be filed on
February 28, 2025, and other periodic
reports filed with the Securities and Exchange Commission. Except
as required by law, the Company does not undertake any obligation
to update or revise any forward-looking statements contained in
this release.
Non-GAAP Financial Measures
The Company's reported results are presented in accordance with
GAAP. The Company also discloses the following Non-GAAP financial
measures: EBITDA, Adjusted EBITDA, Net Debt-to-Annualized Adjusted
EBITDA, NAREIT FFO, NFFO, NOI and Same-Store NOI. The Company
believes these Non-GAAP financial measures are useful supplemental
measures of its operating performance and used by investors and
analysts to compare the operating performance of the Company
between periods and to other REITs or companies on a consistent
basis without having to account for differences caused by
unanticipated and/or incalculable items. Definitions of the
Non-GAAP financial measures used herein and reconciliations to the
most directly comparable financial measure calculated in accordance
with GAAP can be found at the end of this earnings release. See
below for further information regarding the Company's Non-GAAP
financial measures.
EBITDA and Adjusted EBITDA
Management uses earnings before interest, taxes, depreciation
and amortization ("EBITDA") and Adjusted EBITDA to facilitate
internal and external comparisons to our historical operating
results and in making operating decisions. EBITDA and Adjusted
EBITDA are widely used by investors, lenders, credit and equity
analysts in the valuation, comparison, and investment
recommendations of companies. Additionally, EBITDA and Adjusted
EBITDA are utilized by our Board of Directors to evaluate
management. Neither EBITDA nor Adjusted EBITDA represents net
income (loss) or cash flows provided from operating activities as
determined in accordance with GAAP and should not be considered as
alternative measures of profitability or liquidity. Finally, the
EBITDA and Adjusted EBITDA may not be comparable to similarly
entitled items reported by other REITs or other companies. In
addition, management uses Net Debt-to-Annualized Adjusted EBITDA as
a measure of our ability to service our debt.
Funds from Operations (FFO) and Normalized Funds from
Operations (NFFO)
We believe that the use of FFO, which excludes the impact of
real estate-related depreciation and amortization and impairments,
provides a further understanding of our operating performance to
investors, industry analysts and our management, and when compared
year over year, reflects the impact on our operations from trends
in occupancy rates, rental rates, operating costs, general and
administrative expenses and interest costs, which may not be
immediately apparent from net income (loss). However, FFO and NFFO
should not be construed to be (i) more relevant or accurate than
the current GAAP methodology in calculating net income (loss) as an
indicator of our operating performance, (ii) more relevant or
accurate than GAAP cash flows from operations as an indicator of
our liquidity or (iii) indicative of funds available to fund our
cash needs, including our ability to make distributions to our
stockholders. The method utilized to evaluate the value and
performance of real estate under GAAP should be construed as a more
relevant measure of operational performance and considered more
prominently than the Non-GAAP FFO and NFFO measures and the
adjustments to GAAP in calculating FFO and NFFO. Presentation of
this information is intended to provide useful information to
investors, industry analysts and management as they compare the
operating performance metrics used by the REIT industry, although
it should be noted that some REITs may use different methods of
calculating funds from operations and normalized funds from
operations, so comparisons with such REITs may not be
meaningful.
Net Operating Income
We believe that NOI, Cash NOI, Pro-Rata Cash NOI and Same-Store
NOI are appropriate supplemental performance measures to reflect
the performance of our operating assets because NOI, Cash NOI,
Pro-Rata Cash NOI and Same-Store NOI exclude certain items that are
not associated with the operations of the properties. We believe
that NOI, Cash NOI, Pro-Rata Cash NOI and Same-Store NOI are widely
accepted measures of comparative operating performance in the real
estate community and is useful to investors in understanding the
profitability and operating performance of our property portfolio.
However, our use of the terms NOI, Cash NOI, Pro-Rata Cash NOI and
Same-Store NOI may not be comparable to that of other real estate
companies as they may have different methodologies for computing
these amounts.
NOI, Cash NOI, Pro-Rata Cash NOI and Same-Store NOI are not
equivalent to our net income (loss) as determined under GAAP and
may not be a useful measure in measuring operational income or cash
flows. Furthermore, NOI, Cash NOI, Pro-Rata Cash NOI and Same-Store
NOI should not be considered as alternatives to net income (loss)
as an indication of our operating performance or as an alternative
to cash flows from operations as an indication of our liquidity.
NOI, Cash NOI, Pro-Rata Cash NOI and Same-Store NOI should not be
construed to be more relevant or accurate than the GAAP methodology
in calculating net income (loss). NOI, Cash NOI, Pro-Rata Cash NOI
and Same-Store NOI should be reviewed in conjunction with other
measurements as an indication of our performance.
About American Healthcare REIT, Inc.
American Healthcare REIT, Inc. (NYSE: AHR) is a real estate
investment trust that acquires, owns and operates a diversified
portfolio of clinical healthcare real estate, focusing primarily on
senior housing communities, skilled nursing, and outpatient medical
buildings across the United
States, the United Kingdom
and the Isle of Man.
AMERICAN HEALTHCARE
REIT, INC.
|
CONSOLIDATED BALANCE
SHEETS
|
As of December 31,
2024 and 2023
|
(In thousands,
except share and per share amounts) (Unaudited)
|
|
|
December
31,
|
|
2024
|
|
2023
|
ASSETS
|
Real estate
investments, net
|
$
3,366,648
|
|
$
3,425,438
|
Debt security
investment, net
|
91,264
|
|
86,935
|
Cash and cash
equivalents
|
76,702
|
|
43,445
|
Restricted
cash
|
46,599
|
|
47,337
|
Accounts and other
receivables, net
|
211,104
|
|
185,379
|
Identified intangible
assets, net
|
161,473
|
|
180,470
|
Goodwill
|
234,942
|
|
234,942
|
Operating lease
right-of-use assets, net
|
163,987
|
|
227,846
|
Other assets,
net
|
135,338
|
|
146,141
|
Total
assets
|
$
4,488,057
|
|
$
4,577,933
|
|
|
|
|
LIABILITIES,
REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY
|
Liabilities:
|
|
|
|
Mortgage loans
payable, net
|
$
982,071
|
|
$
1,302,396
|
Lines of credit and
term loan, net
|
688,534
|
|
1,223,967
|
Accounts payable and
accrued liabilities
|
258,324
|
|
242,905
|
Identified intangible
liabilities, net
|
3,001
|
|
6,095
|
Financing
obligations
|
34,870
|
|
41,756
|
Operating lease
liabilities
|
165,239
|
|
225,502
|
Security deposits,
prepaid rent and other liabilities
|
51,856
|
|
76,134
|
Total
liabilities
|
2,183,895
|
|
3,118,755
|
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
Redeemable
noncontrolling interests
|
220
|
|
33,843
|
|
|
|
|
Equity:
|
|
|
|
Stockholders'
equity:
|
|
|
|
Preferred stock,
$0.01 par value per share; 200,000,000 shares authorized;
none issued and
outstanding
|
—
|
|
—
|
Common Stock, $0.01
par value per share; 700,000,000 shares authorized; 157,446,697
shares
issued and outstanding as of December 31, 2024
and none issued and outstanding as
of December 31, 2023
|
1,564
|
|
—
|
Class T common stock,
$0.01 par value per share; 200,000,000 shares authorized;
none issued
and outstanding as of December 31, 2024 and
19,552,856 shares issued and outstanding as
of December 31, 2023
|
—
|
|
194
|
Class I common stock,
$0.01 par value per share; 100,000,000 shares authorized; none
issued
and outstanding as of December 31, 2024 and
46,673,320 shares issued and outstanding as
of December 31, 2023
|
—
|
|
467
|
Additional paid-in
capital
|
3,720,268
|
|
2,548,307
|
Accumulated
deficit
|
(1,458,089)
|
|
(1,276,222)
|
Accumulated other
comprehensive loss
|
(2,512)
|
|
(2,425)
|
Total stockholders'
equity
|
2,261,231
|
|
1,270,321
|
Noncontrolling
interests
|
42,711
|
|
155,014
|
Total
equity
|
2,303,942
|
|
1,425,335
|
Total liabilities,
redeemable noncontrolling interests and equity
|
$
4,488,057
|
|
$
4,577,933
|
AMERICAN HEALTHCARE
REIT, INC.
|
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
For the Three Months
Ended and Years Ended December 31, 2024 and
2023
|
(In thousands,
except share and per share amounts) (Unaudited)
|
|
|
Three Months Ended
December 31,
|
|
Year Ended December
31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Revenues and grant
income:
|
|
|
|
|
|
|
|
Resident fees and
services
|
$
496,833
|
|
$
433,284
|
|
$
1,883,798
|
|
$
1,668,742
|
Real estate
revenue
|
45,907
|
|
49,267
|
|
186,870
|
|
190,401
|
Grant
income
|
—
|
|
30
|
|
—
|
|
7,475
|
Total revenues and
grant income
|
542,740
|
|
482,581
|
|
2,070,668
|
|
1,866,618
|
Expenses:
|
|
|
|
|
|
|
|
Property operating
expenses
|
430,572
|
|
385,012
|
|
1,653,893
|
|
1,502,310
|
Rental
expenses
|
13,039
|
|
13,053
|
|
53,239
|
|
57,475
|
General and
administrative
|
12,064
|
|
11,341
|
|
47,559
|
|
47,510
|
Business acquisition
expenses
|
807
|
|
3,551
|
|
7,141
|
|
5,795
|
Depreciation and
amortization
|
46,915
|
|
43,960
|
|
179,192
|
|
182,604
|
Total
expenses
|
503,397
|
|
456,917
|
|
1,941,024
|
|
1,795,694
|
Other income
(expense):
|
|
|
|
|
|
|
|
Interest
expense:
|
|
|
|
|
|
|
|
Interest expense
(including amortization of deferred
financing costs, debt discount/premium and loss
on debt
and derivative extinguishments)
|
(30,301)
|
|
(41,185)
|
|
(127,730)
|
|
(163,191)
|
Gain (loss) in fair
value of derivative financial instruments
|
3,192
|
|
(9,126)
|
|
1,030
|
|
(926)
|
Gain on dispositions
of real estate investments, net
|
2,956
|
|
2,695
|
|
5,213
|
|
32,472
|
Impairment of real
estate investments
|
(45,755)
|
|
(1,389)
|
|
(45,755)
|
|
(13,899)
|
Impairment of
intangible assets
|
—
|
|
(10,520)
|
|
—
|
|
(10,520)
|
Loss from
unconsolidated entities
|
(2,505)
|
|
(794)
|
|
(6,868)
|
|
(1,718)
|
Gain on re-measurement
of previously held equity interest
|
—
|
|
—
|
|
—
|
|
726
|
Foreign currency
(loss) gain
|
(3,119)
|
|
1,935
|
|
(774)
|
|
2,307
|
Other income,
net
|
4,246
|
|
1,649
|
|
11,353
|
|
7,601
|
Total net other
expense
|
(71,286)
|
|
(56,735)
|
|
(163,531)
|
|
(147,148)
|
Loss before income
taxes
|
(31,943)
|
|
(31,071)
|
|
(33,887)
|
|
(76,224)
|
Income tax (expense)
benefit
|
(486)
|
|
112
|
|
(1,713)
|
|
(663)
|
Net
loss
|
(32,429)
|
|
(30,959)
|
|
(35,600)
|
|
(76,887)
|
Net loss (income)
attributable to noncontrolling interests
|
656
|
|
3,534
|
|
(2,212)
|
|
5,418
|
Net loss
attributable to controlling interest
|
$
(31,773)
|
|
$
(27,425)
|
|
$
(37,812)
|
|
$
(71,469)
|
Net loss per share
of Common Stock, Class T common stock and
Class I common stock attributable to
controlling interest:
|
|
|
|
|
|
|
|
Basic
|
$
(0.21)
|
|
$
(0.42)
|
|
$
(0.29)
|
|
$
(1.08)
|
Diluted
|
$
(0.21)
|
|
$
(0.42)
|
|
$
(0.29)
|
|
$
(1.08)
|
Weighted average
number of shares of Common Stock, Class T
common stock and Class I common stock
outstanding:
|
|
|
|
|
|
|
|
Basic
|
153,702,650
|
|
66,079,343
|
|
130,637,539
|
|
66,047,114
|
Diluted
|
153,702,650
|
|
66,079,343
|
|
130,637,539
|
|
66,047,114
|
|
|
|
|
|
|
|
|
Net loss
|
$
(32,429)
|
|
$
(30,959)
|
|
$
(35,600)
|
|
$
(76,887)
|
Other comprehensive
(loss) income:
|
|
|
|
|
|
|
|
Foreign currency
translation adjustments
|
(359)
|
|
199
|
|
(87)
|
|
265
|
Total other
comprehensive (loss) income
|
(359)
|
|
199
|
|
(87)
|
|
265
|
Comprehensive
loss
|
(32,788)
|
|
(30,760)
|
|
(35,687)
|
|
(76,622)
|
Comprehensive loss
(income) attributable to noncontrolling
interests
|
656
|
|
3,534
|
|
(2,212)
|
|
5,418
|
Comprehensive loss
attributable to controlling interest
|
$
(32,132)
|
|
$
(27,226)
|
|
$
(37,899)
|
|
$
(71,204)
|
AMERICAN HEALTHCARE
REIT, INC.
|
FFO and Normalized
FFO Reconciliation
|
For the Three Months
Ended and Years Ended December 31, 2024 and
2023
|
(In thousands,
except share and per share amounts) (Unaudited)
|
|
|
Three Months Ended
December 31,
|
|
Year Ended December
31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Net loss
|
$
(32,429)
|
|
$
(30,959)
|
|
$
(35,600)
|
|
$
(76,887)
|
Depreciation and
amortization related to real estate —
consolidated properties
|
46,877
|
|
43,922
|
|
179,040
|
|
182,452
|
Depreciation and
amortization related to real estate —
unconsolidated entities
|
504
|
|
147
|
|
1,186
|
|
401
|
Impairment of real
estate investments — consolidated
properties
|
45,755
|
|
1,389
|
|
45,755
|
|
13,899
|
Gain on dispositions of
real estate investments, net —
consolidated properties
|
(2,956)
|
|
(2,695)
|
|
(5,213)
|
|
(32,472)
|
Net loss (income)
attributable to noncontrolling interests
|
656
|
|
3,534
|
|
(2,212)
|
|
5,418
|
Gain on re-measurement
of previously held equity interest
|
—
|
|
—
|
|
—
|
|
(726)
|
Depreciation,
amortization, impairments, net gain/loss on
dispositions and gain on re-measurement —
noncontrolling interests
|
(1,986)
|
|
(6,846)
|
|
(17,851)
|
|
(26,518)
|
NAREIT FFO attributable
to controlling interest
|
$
56,421
|
|
$
8,492
|
|
$
165,105
|
|
$
65,567
|
|
|
|
|
|
|
|
|
Business acquisition
expenses
|
$
807
|
|
$
3,551
|
|
$
7,141
|
|
$
5,795
|
Amortization of above-
and below-market leases
|
415
|
|
(2,489)
|
|
1,692
|
|
9,744
|
Amortization of closing
costs — debt security investment
|
86
|
|
74
|
|
324
|
|
278
|
Change in deferred
rent
|
(668)
|
|
(89)
|
|
(2,411)
|
|
1,149
|
Non-cash impact of
changes to equity instruments
|
2,037
|
|
1,377
|
|
9,367
|
|
5,621
|
Capitalized
interest
|
(73)
|
|
(36)
|
|
(334)
|
|
(163)
|
Loss on debt and
derivative extinguishments
|
3,530
|
|
—
|
|
5,382
|
|
345
|
(Gain) loss in fair
value of derivative financial instruments
|
(3,192)
|
|
9,126
|
|
(1,030)
|
|
926
|
Foreign currency loss
(gain)
|
3,119
|
|
(1,935)
|
|
774
|
|
(2,307)
|
Impairment of
intangible assets
|
—
|
|
10,520
|
|
—
|
|
10,520
|
Adjustments for
unconsolidated entities
|
(1)
|
|
38
|
|
(320)
|
|
(321)
|
Adjustments for
noncontrolling interests
|
(85)
|
|
(3,810)
|
|
(768)
|
|
(4,786)
|
Normalized FFO
attributable to controlling interest
|
$
62,396
|
|
$
24,819
|
|
$
184,922
|
|
$
92,368
|
NAREIT FFO and
Normalized FFO weighted average
common shares outstanding — diluted
|
154,449,288
|
|
66,079,343
|
|
131,211,731
|
|
66,047,114
|
NAREIT FFO per common
share attributable to controlling
interest — diluted
|
$
0.37
|
|
$
0.13
|
|
$
1.26
|
|
$
0.99
|
Normalized FFO per
common share attributable to
controlling interest — diluted
|
$
0.40
|
|
$
0.38
|
|
$
1.41
|
|
$
1.40
|
AMERICAN HEALTHCARE
REIT, INC.
|
Adjusted EBITDA
Reconciliation
|
For the Three Months
Ended December 31, 2024
|
(In thousands)
(Unaudited)
|
|
|
|
Net loss
|
|
$
(32,429)
|
Interest expense
(including amortization of deferred financing costs, debt
discount/premium and loss on debt
extinguishments)
|
|
30,301
|
Income tax
expense
|
|
486
|
Depreciation and
amortization (including amortization of leased assets
and accretion of lease liabilities)
|
|
47,376
|
EBITDA
|
|
$
45,734
|
|
|
|
Loss from
unconsolidated entities
|
|
2,505
|
Straight line rent and
amortization of above/below market leases
|
|
(714)
|
Non-cash impact of
changes to equity instruments
|
|
2,037
|
Business acquisition
expenses
|
|
807
|
Gain on dispositions
of real estate investments, net
|
|
(2,956)
|
Amortization of
closing cost - debt security investment
|
|
86
|
Foreign currency
loss
|
|
3,119
|
Gain in fair value of
derivative financial instruments
|
|
(3,192)
|
Impairment of real
estate investments
|
|
45,755
|
Non-recurring one-time
items
|
|
(2,024)
|
|
|
|
Adjusted
EBITDA
|
|
$
91,157
|
AMERICAN HEALTHCARE
REIT, INC.
|
NOI and Cash NOI
Reconciliation
|
For the Three
Months Ended and Years Ended December 31, 2024 and
2023
|
(In thousands)
(Unaudited)
|
|
|
Three Months Ended
December 31,
|
|
Year Ended December
31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Net loss
|
$
(32,429)
|
|
$
(30,959)
|
|
$
(35,600)
|
|
$
(76,887)
|
General and
administrative
|
12,064
|
|
11,341
|
|
47,559
|
|
47,510
|
Business acquisition
expenses
|
807
|
|
3,551
|
|
7,141
|
|
5,795
|
Depreciation and
amortization
|
46,915
|
|
43,960
|
|
179,192
|
|
182,604
|
Interest
expense
|
30,301
|
|
41,185
|
|
127,730
|
|
163,191
|
(Gain) loss in fair
value of derivative financial instruments
|
(3,192)
|
|
9,126
|
|
(1,030)
|
|
926
|
Gain on dispositions of
real estate investments, net
|
(2,956)
|
|
(2,695)
|
|
(5,213)
|
|
(32,472)
|
Impairment of real
estate investments
|
45,755
|
|
1,389
|
|
45,755
|
|
13,899
|
Impairment of
intangible assets
|
—
|
|
10,520
|
|
—
|
|
10,520
|
Loss from
unconsolidated entities
|
2,505
|
|
794
|
|
6,868
|
|
1,718
|
Gain on re-measurement
of previously held equity interest
|
—
|
|
—
|
|
—
|
|
(726)
|
Foreign currency loss
(gain)
|
3,119
|
|
(1,935)
|
|
774
|
|
(2,307)
|
Other income,
net
|
(4,246)
|
|
(1,649)
|
|
(11,353)
|
|
(7,601)
|
Income tax expense
(benefit)
|
486
|
|
(112)
|
|
1,713
|
|
663
|
Net operating
income
|
$
99,129
|
|
$
84,516
|
|
$
363,536
|
|
$
306,833
|
|
|
|
|
|
|
|
|
Grant Income
|
—
|
|
(30)
|
|
—
|
|
(7,475)
|
Total NOI (excluding
Grant Income)
|
$
99,129
|
|
$
84,486
|
|
$
363,536
|
|
$
299,358
|
|
|
|
|
|
|
|
|
Straight line
rent
|
(672)
|
|
(584)
|
|
(3,234)
|
|
(3,481)
|
Facility rental
expense
|
7,642
|
|
8,774
|
|
31,989
|
|
37,025
|
Other non-cash
adjustments
|
158
|
|
(2,397)
|
|
1,187
|
|
9,946
|
COVID
subsidies
|
—
|
|
—
|
|
—
|
|
(171)
|
Cash NOI from
dispositions
|
(2,508)
|
|
—
|
|
(2,508)
|
|
—
|
Cash NOI attributable
to noncontrolling interests(1)
|
(271)
|
|
(242)
|
|
(1,016)
|
|
(895)
|
Cash NOI
|
$
103,478
|
|
$
90,037
|
|
$
389,954
|
|
$
341,782
|
|
|
|
|
|
|
(1)
|
All periods are based
upon current quarter's ownership percentage.
|
AMERICAN HEALTHCARE
REIT, INC.
|
Same-Store NOI
Reconciliation
|
For the Three Months
Ended and Years Ended December 31, 2024 and 2023
|
(In thousands)
(Unaudited)
|
|
|
Three Months Ended
December 31,
|
|
Year Ended December
31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
ISHC
|
|
|
|
|
|
|
|
NOI (excluding Grant
Income)
|
$
53,586
|
|
$
41,766
|
|
$
189,273
|
|
$
146,063
|
Facility rental
expense
|
7,642
|
|
8,774
|
|
31,989
|
|
37,025
|
Cash NOI from
dispositions
|
(341)
|
|
—
|
|
(341)
|
|
—
|
Cash NOI
(1)
|
$
60,887
|
|
$
50,540
|
|
$
220,921
|
|
$
183,088
|
New
acquisitions/dispositions/transitions/other
(1)
|
(6,266)
|
|
(6,709)
|
|
(24,153)
|
|
(24,975)
|
Non-Core Properties
(1)
|
(928)
|
|
(460)
|
|
(4,007)
|
|
(160)
|
Other normalizing
adjustments (1)
|
—
|
|
(1,429)
|
|
974
|
|
(1,429)
|
Same-Store NOI
(1)
|
$
53,693
|
|
$
41,942
|
|
$
193,735
|
|
$
156,524
|
|
|
|
|
|
|
|
|
Outpatient
Medical
|
|
|
|
|
|
|
|
NOI
|
$
20,800
|
|
$
23,825
|
|
$
83,855
|
|
$
91,611
|
Straight line
rent
|
(134)
|
|
(291)
|
|
(568)
|
|
(1,320)
|
Other non-cash
adjustments
|
(81)
|
|
(2,633)
|
|
252
|
|
(1,959)
|
Cash NOI from
dispositions
|
(261)
|
|
—
|
|
(261)
|
|
—
|
Cash NOI
(2)
|
$
20,324
|
|
$
20,901
|
|
$
83,278
|
|
$
88,332
|
New
acquisitions/dispositions/transitions
|
—
|
|
(802)
|
|
(2,119)
|
|
(7,664)
|
Non-Core
Properties
|
(335)
|
|
(373)
|
|
(1,506)
|
|
(1,406)
|
Same-Store NOI
(2)
|
$
19,989
|
|
$
19,726
|
|
$
79,653
|
|
$
79,262
|
|
|
|
|
|
|
|
|
SHOP
|
|
|
|
|
|
|
|
NOI
|
$
12,675
|
|
$
6,506
|
|
$
40,632
|
|
$
20,369
|
Other non-cash
adjustments
|
—
|
|
11
|
|
—
|
|
5
|
COVID
subsidies
|
—
|
|
—
|
|
—
|
|
(171)
|
Cash NOI attributable
to noncontrolling interests (2)
|
(80)
|
|
(56)
|
|
(264)
|
|
(158)
|
Cash NOI
|
$
12,595
|
|
$
6,461
|
|
$
40,368
|
|
$
20,045
|
New
acquisitions/dispositions/transitions
|
(3,236)
|
|
(1,010)
|
|
(7,256)
|
|
1,474
|
Development
conversion
|
576
|
|
340
|
|
2,290
|
|
1,551
|
Other normalizing
adjustments
|
—
|
|
171
|
|
233
|
|
257
|
Same-Store
NOI
|
$
9,935
|
|
$
5,962
|
|
$
35,635
|
|
$
23,327
|
|
|
|
|
|
|
|
|
Triple-Net Leased
Properties
|
|
|
|
|
|
|
|
NOI
|
$
12,068
|
|
$
12,389
|
|
$
49,776
|
|
$
41,315
|
Straight line
rent
|
(538)
|
|
(293)
|
|
(2,666)
|
|
(2,161)
|
Other non-cash
adjustments
|
239
|
|
225
|
|
935
|
|
11,900
|
Cash NOI from
dispositions
|
(1,906)
|
|
—
|
|
(1,906)
|
|
—
|
Cash NOI attributable
to noncontrolling interest (2)
|
(191)
|
|
(186)
|
|
(752)
|
|
(737)
|
Cash NOI
|
$
9,672
|
|
$
12,135
|
|
$
45,387
|
|
$
50,317
|
Debt security
investment
|
(2,117)
|
|
(2,011)
|
|
(8,690)
|
|
(8,040)
|
New
acquisitions/dispositions/transitions
|
—
|
|
(2,708)
|
|
(6,454)
|
|
(12,996)
|
Non-Core
Properties
|
(379)
|
|
(359)
|
|
(1,495)
|
|
(1,413)
|
Same-Store
NOI
|
$
7,176
|
|
$
7,057
|
|
$
28,748
|
|
$
27,868
|
AMERICAN HEALTHCARE
REIT, INC.
|
Same-Store NOI
Reconciliation - (Continued)
|
For the Three Months
Ended and Years Ended December 31, 2024 and 2023
|
(In thousands)
(Unaudited)
|
|
|
Three Months Ended
December 31,
|
|
Year Ended December
31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Total
Portfolio
|
|
|
|
|
|
|
|
NOI (excluding Grant
Income)
|
$
99,129
|
|
$
84,486
|
|
$
363,536
|
|
$
299,358
|
Straight line
rent
|
(672)
|
|
(584)
|
|
(3,234)
|
|
(3,481)
|
Facility rental
expense
|
7,642
|
|
8,774
|
|
31,989
|
|
37,025
|
Other non-cash
adjustments
|
158
|
|
(2,397)
|
|
1,187
|
|
9,946
|
COVID
subsidies
|
—
|
|
—
|
|
—
|
|
(171)
|
Cash NOI from
dispositions
|
(2,508)
|
|
—
|
|
(2,508)
|
|
—
|
Cash NOI attributable
to noncontrolling interests (2)
|
(271)
|
|
(242)
|
|
(1,016)
|
|
(895)
|
Cash NOI
(1)(2)
|
$
103,478
|
|
$
90,037
|
|
$
389,954
|
|
$
341,782
|
Debt security
investment
|
(2,117)
|
|
(2,011)
|
|
(8,690)
|
|
(8,040)
|
New
acquisitions/dispositions/transitions/other
(1)
|
(9,502)
|
|
(11,229)
|
|
(39,982)
|
|
(44,161)
|
Development
conversion
|
576
|
|
340
|
|
2,290
|
|
1,551
|
Non-Core Properties
(1)
|
(1,642)
|
|
(1,192)
|
|
(7,008)
|
|
(2,979)
|
Other normalizing
adjustments (1)
|
—
|
|
(1,258)
|
|
1,207
|
|
(1,172)
|
Same-Store NOI
(1)(2)
|
$
90,793
|
|
$
74,687
|
|
$
337,771
|
|
$
286,981
|
|
|
|
|
|
|
(1)
|
Prior periods'
information is presented to reflect the increase in ownership to
100% in the Company's ISHC segment effective September
2024.
|
(2)
|
All periods are based
upon current quarter's ownership percentage.
|
AMERICAN HEALTHCARE
REIT, INC.
|
Same-Store Revenue
Reconciliation
|
For the Three
Months Ended and Years Ended December 31, 2024 and
2023
|
(In thousands)
(Unaudited)
|
|
|
Three Months Ended
December 31,
|
|
Year Ended December
31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
ISHC
|
|
|
|
|
|
|
|
GAAP revenue and Grant
Income
|
$
423,290
|
|
$
384,993
|
|
$
1,619,812
|
|
$
1,489,355
|
Grant Income
|
—
|
|
(30)
|
|
—
|
|
(7,475)
|
Cash revenue from
dispositions
|
(1,774)
|
|
—
|
|
(1,774)
|
|
—
|
Cash revenue
(1)
|
$
421,516
|
|
$
384,963
|
|
$
1,618,038
|
|
$
1,481,880
|
Revenue attributable to
non-Same-Store properties (1)
|
(128,772)
|
|
(117,025)
|
|
(491,479)
|
|
(441,605)
|
Revenue attributable to
Non-Core Properties (1)
|
(8,098)
|
|
(6,926)
|
|
(31,251)
|
|
(25,237)
|
Other normalizing
revenue adjustments (1)
|
—
|
|
—
|
|
(1,236)
|
|
—
|
Same-Store revenue
(1)
|
$
284,646
|
|
$
261,012
|
|
$
1,094,072
|
|
$
1,015,038
|
|
|
|
|
|
|
|
|
Outpatient
Medical
|
|
|
|
|
|
|
|
GAAP revenue
|
$
33,276
|
|
$
36,257
|
|
$
134,740
|
|
$
146,068
|
Straight line
rent
|
(134)
|
|
(291)
|
|
(568)
|
|
(1,320)
|
Other non-cash
adjustments
|
(399)
|
|
(2,995)
|
|
(1,113)
|
|
(3,349)
|
Cash revenue from
dispositions
|
(304)
|
|
—
|
|
(304)
|
|
—
|
Cash revenue
(2)
|
$
32,439
|
|
$
32,971
|
|
$
132,755
|
|
$
141,399
|
Revenue attributable to
non-Same-Store properties
|
—
|
|
(1,197)
|
|
(3,029)
|
|
(12,721)
|
Revenue attributable to
Non-Core Properties
|
(479)
|
|
(482)
|
|
(2,004)
|
|
(1,892)
|
Same-Store revenue
(2)
|
$
31,960
|
|
$
31,292
|
|
$
127,722
|
|
$
126,786
|
|
|
|
|
|
|
|
|
SHOP
|
|
|
|
|
|
|
|
GAAP revenue
|
$
73,543
|
|
$
48,321
|
|
$
263,986
|
|
$
186,862
|
Cash revenue
attributable to noncontrolling interests (2)
|
(304)
|
|
(271)
|
|
(1,167)
|
|
(1,287)
|
Cash revenue
|
$
73,239
|
|
$
48,050
|
|
$
262,819
|
|
$
185,575
|
Revenue attributable to
non-Same-Store properties
|
(27,955)
|
|
(7,692)
|
|
(86,922)
|
|
(28,178)
|
Revenue attributable to
development conversion
|
(491)
|
|
(183)
|
|
(1,587)
|
|
(1,451)
|
Same-Store
revenue
|
$
44,793
|
|
$
40,175
|
|
$
174,310
|
|
$
155,946
|
|
|
|
|
|
|
|
|
Triple-Net Leased
Properties
|
|
|
|
|
|
|
|
GAAP revenue
|
$
12,631
|
|
$
13,010
|
|
$
52,130
|
|
$
44,333
|
Straight line
rent
|
(538)
|
|
(293)
|
|
(2,666)
|
|
(2,161)
|
Other non-cash
adjustments
|
220
|
|
206
|
|
859
|
|
11,833
|
Cash revenue from
dispositions
|
(1,910)
|
|
—
|
|
(1,910)
|
|
—
|
Cash revenue
attributable to noncontrolling interest (2)
|
(190)
|
|
(186)
|
|
(752)
|
|
(738)
|
Cash revenue
|
$
10,213
|
|
$
12,737
|
|
$
47,661
|
|
$
53,267
|
Debt security
investment
|
(2,117)
|
|
(2,011)
|
|
(8,690)
|
|
(8,040)
|
Revenue attributable to
non-Same-Store properties
|
—
|
|
(2,757)
|
|
(6,507)
|
|
(13,662)
|
Revenue attributable to
Non-Core Properties
|
(499)
|
|
(445)
|
|
(1,881)
|
|
(1,802)
|
Same-Store
revenue
|
$
7,597
|
|
$
7,524
|
|
$
30,583
|
|
$
29,763
|
AMERICAN HEALTHCARE
REIT, INC.
|
Same-Store Revenue
Reconciliation - (Continued)
|
For the Three Months
Ended and Years Ended December 31, 2024 and 2023
|
(In thousands)
(Unaudited)
|
|
|
Three Months Ended
December 31,
|
|
Year Ended December
31,
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
Total
Portfolio
|
|
|
|
|
|
|
|
GAAP revenue and Grant
Income
|
$
542,740
|
|
$
482,581
|
|
$
2,070,668
|
|
$
1,866,618
|
Straight line
rent
|
(672)
|
|
(584)
|
|
(3,234)
|
|
(3,481)
|
Other non-cash
adjustments
|
(179)
|
|
(2,789)
|
|
(254)
|
|
8,484
|
Grant Income
|
—
|
|
(30)
|
|
—
|
|
(7,475)
|
Cash revenue from
dispositions
|
(3,988)
|
|
—
|
|
(3,988)
|
|
—
|
Cash revenue
attributable to noncontrolling interests (2)
|
(494)
|
|
(457)
|
|
(1,919)
|
|
(2,025)
|
Cash revenue
(1)(2)
|
$
537,407
|
|
$
478,721
|
|
$
2,061,273
|
|
$
1,862,121
|
Debt security
investment
|
(2,117)
|
|
(2,011)
|
|
(8,690)
|
|
(8,040)
|
Revenue attributable to
non-Same-Store properties (1)
|
(156,727)
|
|
(128,671)
|
|
(587,937)
|
|
(496,166)
|
Revenue attributable to
development conversion
|
(491)
|
|
(183)
|
|
(1,587)
|
|
(1,451)
|
Revenue attributable to
Non-Core Properties (1)
|
(9,076)
|
|
(7,853)
|
|
(35,136)
|
|
(28,931)
|
Other normalizing
revenue adjustments (1)
|
—
|
|
—
|
|
(1,236)
|
|
—
|
Same-Store revenue
(1)(2)
|
$
368,996
|
|
$
340,003
|
|
$
1,426,687
|
|
$
1,327,533
|
|
|
|
|
|
|
(1)
|
Prior periods'
information is presented to reflect the increase in ownership to
100% in the Company's ISHC segment effective September
2024.
|
(2)
|
All periods are based
upon current quarter's ownership percentage.
|
AMERICAN HEALTHCARE
REIT, INC.
|
Earnings Guidance
Reconciliation
|
For the Year Ending
December 31, 2025
|
(Dollars and shares
in millions, except per share amounts) (Unaudited)
|
|
|
Full Year
2025 Guidance
|
|
Low
|
|
High
|
Net income attributable
to common stockholders
|
$
40.59
|
|
$
46.71
|
Depreciation and
amortization(1)
|
192.49
|
|
192.49
|
NAREIT FFO attributable
to common stockholders
|
$
233.08
|
|
$
239.20
|
|
|
|
|
Amortization of other
intangible assets/liabilities(1)
|
$
1.89
|
|
$
1.89
|
Change in deferred
rent(1)
|
(1.00)
|
|
(1.00)
|
Non-cash impact of
changes to equity plan(1)(2)
|
8.96
|
|
8.96
|
Other
adjustments(3)
|
1.26
|
|
1.26
|
Normalized FFO
attributable to common stockholders
|
$
244.19
|
|
$
250.31
|
|
|
|
|
Net income per common
share — diluted
|
$
0.26
|
|
$
0.30
|
|
|
|
|
NAREIT FFO per common
share — diluted
|
$
1.49
|
|
$
1.53
|
|
|
|
|
Normalized FFO per
common share — diluted
|
$
1.56
|
|
$
1.60
|
|
|
|
|
NAREIT FFO and
Normalized FFO weighted average shares — diluted
|
156.4
|
|
156.4
|
|
|
|
|
Total Portfolio
Same-Store NOI growth
|
7.0 %
|
|
10.0 %
|
|
|
|
|
Segment-Level
Same-Store NOI growth / (decline):
|
|
|
|
ISHC
|
10.0 %
|
|
12.0 %
|
Outpatient
Medical
|
(1.0 %)
|
|
1.0 %
|
SHOP
|
18.0 %
|
|
22.0 %
|
Triple-Net Leased
Properties
|
(1.5 %)
|
|
(0.5 %)
|
|
|
|
|
|
|
(1)
|
Amounts presented net
of noncontrolling interests' share and AHR's share of
unconsolidated entities.
|
(2)
|
Amounts represent
amortization of equity compensation and fair value adjustments to
performance-based equity compensation.
|
(3)
|
Includes adjustments
for capitalized interest, business acquisition expenses and
additional items as noted in the Company's definition for
NFFO.
|
Definitions
Adjusted EBITDA: EBITDA excluding the impact of gain or
loss from unconsolidated entities, straight line rent and
amortization of above/below market leases, non-cash stock-based
compensation expense, business acquisition expenses, gain or loss
on sales of real estate investments, unrealized foreign currency
gain or loss, change in fair value of derivative financial
instruments, impairments of real estate investments, impairments of
intangible assets and goodwill, and non-recurring one-time
items.
Cash NOI: NOI excluding the impact of, without
duplication, (1) non-cash items such as straight-line rent and the
amortization of lease intangibles, (2) third-party facility rent
payments and (3) other items set forth in the Cash NOI
reconciliation included herein. Both Cash NOI and Same-Store NOI
include Pro-Rata ownership and other adjustments.
EBITDA: A Non-GAAP financial measure that is defined as
earnings before interest, taxes, depreciation and amortization.
GAAP revenue: Revenue recognized in accordance with
Generally Accepted Accounting Principles ("GAAP"), which includes
straight line rent and other non-cash adjustments.
ISHC: Integrated senior health campuses include a range
of senior care, including independent living, assisted living,
memory care, skilled nursing services and certain ancillary
businesses. Integrated senior health campuses are operated
utilizing a RIDEA structure.
MSA: Metropolitan statistical area; a geographic area
defined by the United States Office of Management and Budget that
includes a city with at least 50,000 people and the surrounding
counties with economic ties. MSAs are used to group cities and
counties for statistical data and population censuses.
NAREIT FFO or FFO: Funds from operations attributable
to controlling interest; a Non-GAAP financial measure, consistent
with the standards established by the White Paper on FFO approved
by the Board of Governors of NAREIT (the "White Paper"). The White
Paper defines FFO as net income (loss) computed in accordance with
GAAP, excluding gains or losses from sales of certain real estate
assets, gains or losses upon consolidation of a previously held
equity interest, and impairment write-downs of certain real estate
assets and investments, plus depreciation and amortization related
to real estate, after adjustments for unconsolidated partnerships
and joint ventures. While impairment charges are excluded from the
calculation of FFO as described above, investors are cautioned that
impairments are based on estimated future undiscounted cash flows.
Adjustments for unconsolidated partnerships and joint ventures are
calculated to reflect FFO.
Net Debt: Total long-term debt, excluding operating lease
liabilities, less cash and cash equivalents and restricted cash
related to debt.
NOI: Net operating income; a Non-GAAP financial measure that
is defined as net income (loss), computed in accordance with GAAP,
generated from properties before general and administrative
expenses, business acquisition expenses, depreciation and
amortization, interest expense, gain or loss in fair value of
derivative financial instruments, gain or loss on dispositions,
impairments of real estate investments, impairments of intangible
assets and goodwill, income or loss from unconsolidated entities,
gain on re-measurement of previously held equity interest, foreign
currency gain or loss, other income or expense and income tax
benefit or expense.
Non-Core Properties: Assets that have been deemed not
essential to generating future economic benefit or value to our
day-to-day operations and/or are projected to be sold.
Normalized FFO attributable to controlling interest or
NFFO: FFO further adjusted for the following items
included in the determination of GAAP net income (loss): expensed
acquisition fees and costs, which we refer to as business
acquisition expenses; amounts relating to changes in deferred rent
and amortization of above and below-market leases (which are
adjusted in order to reflect such payments from a GAAP accrual
basis); the non-cash impact of changes to our equity instruments;
non-cash or non-recurring income or expense; the noncash effect of
income tax benefits or expenses; capitalized interest; impairments
of intangible assets and goodwill; amortization of closing costs on
debt investments; mark-to-market adjustments included in net income
(loss); gains or losses included in net income (loss) from the
extinguishment or sale of debt, hedges, foreign exchange,
derivatives or securities holdings where trading of such holdings
is not a fundamental attribute of the business plan; and after
adjustments for consolidated and unconsolidated partnerships and
joint ventures, with such adjustments calculated to reflect
Normalized FFO on the same basis.
Occupancy: With respect to OM, the percentage of total
rentable square feet leased and occupied, including month-to-month
leases, as of the date reported. With respect to all other property
types, occupancy represents average quarterly operating occupancy
based on the most recent quarter of available data. The Company
uses unaudited, periodic financial information provided solely by
tenants to calculate occupancy and has not independently verified
the information. Occupancy metrics are reflected at our Pro-Rata
share.
Outpatient Medical or OM: Outpatient Medical buildings.
Pro-Rata: As of December 31, 2024, we owned and/or
operated eight buildings through entities of which we owned between
90.0% and 98.0% of the ownership interests. Because we have a
controlling interest in these entities, these entities and the
properties these entities own are consolidated in our financial
statements in accordance with GAAP. However, while such properties
are presented in our financial statements on a consolidated basis,
we are only entitled to our Pro-Rata share of the net cash flows
generated by such properties. As a result, we have presented
certain property information herein based on our Pro-Rata ownership
interest in these entities and the properties these entities own,
as of the applicable date, and not on a consolidated basis. In such
instances, information is noted as being presented on a "Pro-Rata
share" basis.
RevPOR: Revenue per occupied room. RevPOR is calculated
as total revenue generated by occupied rooms divided by the number
of occupied rooms.
RIDEA: Used to describe properties within the portfolio
that utilize the RIDEA structure as described in "RIDEA
structure".
RIDEA structure: A structure permitted by the REIT
Investment Diversification and Empowerment Act of 2007, pursuant to
which we lease certain healthcare real estate properties to a
wholly-owned taxable REIT subsidiary ("TRS"), which in turn
contracts with an eligible independent contractor ("EIK") to
operate such properties for a fee. Under this structure, the EIK
receives management fees, and the TRS receives revenue from the
operation of the healthcare real estate properties and retains, as
profit, any revenue remaining after payment of expenses (including
intercompany rent paid to us and any taxes at the TRS level)
necessary to operate the property. Through the RIDEA structure, in
addition to receiving rental revenue from the TRS, we retain any
after-tax profit from the operation of the healthcare real estate
properties and benefit from any improved operational performance
while bearing the risk of any decline in operating performance at
the properties.
Same-Store or SS: Properties owned or consolidated the full
year in both comparison years and that are not otherwise excluded.
Properties are excluded from Same-Store if they are: (1) sold,
classified as held for sale or properties whose operations were
classified as discontinued operations in accordance with GAAP; (2)
impacted by materially disruptive events, such as flood or fire for
an extensive period of time; or (3) scheduled to undergo or
currently undergoing major expansions/renovations or business model
transitions or have transitioned business models after the start of
the prior comparison period.
Same-Store NOI or SS NOI: Cash NOI for our Same-Store
properties. Same-Store NOI is used to evaluate the operating
performance of our properties using a consistent population which
controls for changes in the composition of our portfolio. Both Cash
NOI and Same-Store NOI include ownership and other adjustments.
SHOP: Senior housing operating properties.
Square Feet or Sq. Ft.: Net rentable square feet
calculated utilizing Building Owners and Managers Association
measurement standards.
Total Debt: The principal balances of the Company's
revolving credit facility, term loan and secured indebtedness as
reported in the Company's consolidated financial statements.
Trilogy: Trilogy Investors, LLC; one of our consolidated
subsidiaries, in which we indirectly owned a 100% interest as of
December 31, 2024.
Trilogy REIT Holdings or Trilogy Holdings: Trilogy REIT
Holdings, LLC, which indirectly owned a 100% interest in Trilogy as
of December 31, 2024.
Triple-net leased: A lease where the tenant is
responsible for making rent payments, maintaining the leased
property, and paying property taxes and other expenses.
Contact: Alan
Peterson
Email:
investorrelations@ahcreit.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/american-healthcare-reit-ahr-announces-fourth-quarter-2024-and-full-year-2024-results-issues-full-year-2025-guidance-302387956.html
SOURCE American Healthcare REIT, Inc.